Barclays
DNLI icon

Barclays’s Denali Therapeutics DNLI Stock Holding History

Barclays’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,500
Closed -$483K – 5145
2023
Q4 		$483K Buy
+22,500
New +$446K ﹤0.01% 3898

Other funds holding DNLI

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Barclays's DNLI Position: Q3 2026 in Review

Barclays increased its Denali Therapeutics (DNLI) stake by 81% in Q3 2026, buying an estimated $1.6M and bringing the position to 153,357 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2298.

Barclays first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $16.3M in Q4 2022. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Barclays held 153,357 shares of Denali Therapeutics worth $3.17M as of Q3 2026.
  • Barclays bought 68,465 Denali Therapeutics shares in Q3 2026, an estimated $1.6M.
  • Denali Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2298 holding.
  • Barclays first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
  • Barclays's Denali Therapeutics position peaked at $16.3M in Q4 2022.
  • 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.